Chang Su

Chang Su

Auto-generated profile, based on publicly available information

Chang Su

Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine, Department of Medicine, University of California San Francisco Medical Center, San Francisco, Calif

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2018 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
KCKen Chang
Ken Chang
HBHarrison X. Bai
Harrison X. Bai
HZHao Zhou
Hao Zhou
CSChang Su
Chang Su
WBWenya Linda Bi
Wenya Linda Bi
JKJayashree Kalpathy-Cramer
Jayashree Kalpathy-Cramer
Purpose: Isocitrate dehydrogenase (IDH) mutations in glioma patients confer longer survival and may guide treatment decision making. We aimed to predict the IDH status of gliomas from MR imaging by applying a residual convolutional neural network to preoperative radiographic data. Experimental Design: Preoperative imaging was acquired for 201 patients from the Hospital of University of Pennsylvania (HUP), 157 patients from Brigham and Women's Hospital (BWH), and 138 patients from The Cancer Imaging Archive (TCIA) and divided into training, validation, and testing sets. We trained a residual convolutional neural network for each MR sequence (FLAIR, T2, T1 precontrast, and T1 postcontrast) and built a predictive model from the outputs. To increase the size of the training set and prevent overfitting, we augmented the training set images by introducing random rotations, translations, flips, shearing, and zooming. Results: With our neural network model, we achieved IDH prediction accuracies of 82.8% (AUC = 0.90), 83.0% (AUC = 0.93), and 85.7% (AUC = 0.94) within training, validation, and testing sets, respectively. When age at diagnosis was incorporated into the model, the training, validation, and testing accuracies increased to 87.3% (AUC = 0.93), 87.6% (AUC = 0.95), and 89.1% (AUC = 0.95), respectively. Conclusions: We developed a deep learning technique to noninvasively predict IDH genotype in grade II–IV glioma using conventional MR imaging using a multi-institutional data set. Clin Cancer Res; 24(5); 1073–81. ©2017 AACR.

24 January 2017 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
HZHao Zhou
Hao Zhou
MVMartin Vallières
Martin Vallières
HBHarrison X. Bai
Harrison X. Bai
CSChang Su
Chang Su
HTHaiyun Tang
Haiyun Tang
LYLi Yang
Li Yang
Previous studies have shown that MR imaging features can be used to predict survival and molecular profile of glioblastoma. However, no study of a similar type has been performed on lower-grade gliomas (LGGs). Presurgical MRIs of 165 patients with diffuse low- and intermediate-grade gliomas (histological grades II and III) were scored according to the Visually Accessible Rembrandt Images (VASARI) annotations. Radiomic models using automated texture analysis and VASARI features were built to predict isocitrate dehydrogenase 1 (IDH1) mutation, 1p/19q codeletion status, histological grade, and tumor progression. Interrater analysis showed significant agreement in all imaging features scored (k = 0.703–1.000). On multivariate Cox regression analysis, no enhancement and a smooth non-enhancing margin were associated with longer progression-free survival (PFS), while a smooth non-enhancing margin was associated with longer overall survival (OS) after taking into account age, grade, tumor location, histology, extent of resection, and IDH1 1p/19q subtype. Using logistic regression and bootstrap testing evaluations, texture models were found to possess higher prediction potential for IDH1 mutation, 1p/19q codeletion status, histological grade, and progression of LGGs than VASARI features, with areas under the receiver-operating characteristic curves of 0.86 ± 0.01, 0.96 ± 0.01, 0.86 ± 0.01, and 0.80 ± 0.01, respectively. No enhancement and a smooth non-enhancing margin on MRI were predictive of longer PFS, while a smooth non-enhancing margin was a significant predictor of longer OS in LGGs. Textural analyses of MR imaging data predicted IDH1 mutation, 1p/19q codeletion, histological grade, and tumor progression with high accuracy.

13 June 2019 in Neuro-Oncology
Verified
Journal Article
Open access
KCKen Chang
Ken Chang
ABAndrew L Beers
Andrew L Beers
HBHarrison X Bai
Harrison X Bai
JBJames M Brown
James M Brown
KLK Ina Ly
K Ina Ly
JKJayashree Kalpathy-Cramer
Jayashree Kalpathy-Cramer
Background: Longitudinal measurement of glioma burden with MRI is the basis for treatment response assessment. In this study, we developed a deep learning algorithm that automatically segments abnormal fluid attenuated inversion recovery (FLAIR) hyperintensity and contrast-enhancing tumor, quantitating tumor volumes as well as the product of maximum bidimensional diameters according to the Response Assessment in Neuro-Oncology (RANO) criteria (AutoRANO). Methods: Two cohorts of patients were used for this study. One consisted of 843 preoperative MRIs from 843 patients with low- or high-grade gliomas from 4 institutions and the second consisted of 713 longitudinal postoperative MRI visits from 54 patients with newly diagnosed glioblastomas (each with 2 pretreatment “baseline” MRIs) from 1 institution. Results: The automatically generated FLAIR hyperintensity volume, contrast-enhancing tumor volume, and AutoRANO were highly repeatable for the double-baseline visits, with an intraclass correlation coefficient (ICC) of 0.986, 0.991, and 0.977, respectively, on the cohort of postoperative GBM patients. Furthermore, there was high agreement between manually and automatically measured tumor volumes, with ICC values of 0.915, 0.924, and 0.965 for preoperative FLAIR hyperintensity, postoperative FLAIR hyperintensity, and postoperative contrast-enhancing tumor volumes, respectively. Lastly, the ICCs for comparing manually and automatically derived longitudinal changes in tumor burden were 0.917, 0.966, and 0.850 for FLAIR hyperintensity volume, contrast-enhancing tumor volume, and RANO measures, respectively. Conclusions: Our automated algorithm demonstrates potential utility for evaluating tumor burden in complex posttreatment settings, although further validation in multicenter clinical trials will be needed prior to widespread implementation.

1 September 2017 in Journal of the American Academy of Dermatology
Verified
Journal Article
Closed access
CSChang Su
Chang Su
KNKevin A. Nguyen
Kevin A. Nguyen
HBHarrison X. Bai
Harrison X. Bai
YCYa Cao
Ya Cao
YTYongguang Tao
Yongguang Tao
GZGuiying Zhang
Guiying Zhang

30 March 2018 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
KNKevin A. Nguyen
Kevin A. Nguyen
CSChang Su
Chang Su
HBHarrison X. Bai
Harrison X. Bai
ZZZishu Zhang
Zishu Zhang
RXRong Xiao
Rong Xiao
GZGuiying Zhang
Guiying Zhang

2 November 2015 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
LYLi Yang
Li Yang
CSChang Su
Chang Su
ALAshley M. Lee
Ashley M. Lee
HBHarrison X. Bai
Harrison X. Bai
The Chinese researchers have made significant progress in studying rare diseases in the recent years. From 2000 to 2014, 269 out of 1892 clinically relevant original research papers published on high impact journals by Chinese institutions, and 2678 out of 6040 clinical trials conducted by Chinese institutions and registered at ClinicalTrial.gov are focused on rare diseases. The number of research papers and of clinical trials has shown a steady trend of increase. Creating public databases for rare disease will escalate progress in rare disease and enable multicenter studies.